Hylomorph introduces Vesta™: a next-generation absorbable antibacterial envelope for CIEDs

ZURICH - Oct. 16, 2025 - PRLog -- A new study published in Europace, the official journal of the European Society of Cardiology, reports promising preclinical results for Vesta™, an innovative antibacterial and absorbable envelope developed by Hylomorph AG for cardiac implantable electronic devices (CIEDs).
The research, led by Dr. Robert D. Schaller from Penn Medicine (Philadelphia, PA) and Dr. Alexander Breitenstein from the University Hospital Zurich (Switzerland), demonstrates Vesta™'s antimicrobial activity and enhanced mechanical compliance in preclinical models.

Vesta™ is an absorbable antibacterial envelope that combines the sustained elution of antimicrobial molecules with enhanced biomechanical properties.

Key preclinical findings

• Antimicrobial efficacy: Vesta™ achieved complete bacterial inhibition against clinically relevant strains responsible for biofilm formation and infection onset.
• Sustained antibiotic release: The drug load was gradually released over 7 days.
• Superior conformability and form-factor: Vesta™ adapted seamlessly to non-planar surfaces, showing improved conformability, which facilitates handling during implantation.
• Biocompatibility and absorption: Histological assessment showed normal healing, complete absorption, and no evidence of inflammation or migration.

Researcher comment
"CIED infection remains one of the most serious and costly complications in cardiac device
therapy." said Dr. Robert D. Schaller, lead author of the study. "Our preclinical results with
Vesta™ suggest that it is possible to combine effective antimicrobial protection with superior mechanical compliance. This represents an encouraging step toward reducing infection risk without compromising ease of use or tissue healing"

Company statement
"At Hylomorph we aim at bridging biomaterials science and clinical need," said Aldo Ferrari,
Chief Scientific Officer of Hylomorph AG. "Vesta™ exemplifies how intelligent design can
advance both device performance and the potential for improved patient outcomes. These
preclinical results confirm the potential of our technology platform to address one of the most persistent challenges in CIED implantation. "

About Hylomorph
Hylomorph AG is a medical technology company based in Zurich, Switzerland, focused on
developing biomaterial-based solutions to improve the long-term performance and safety of
implantable medical devices.
The flagship product Vesta™ combines bioengineering and regenerative medicine to create compliant, bioabsorbable devices that may reduce post-operative complications in CIED implants.

Reference:
Schaller R.D., Mittal S., Biffi M., Ziacchi M., Kirchhof N., Ferrari A., Breitenstein A. Preclinical evaluation of a compliant and absorbable CIED antibacterial envelope. Europace (2025). Oxford University Press, European Society of Cardiology.
https://academic.oup.com/europace/advance-article/doi/10....